This is a summary of the European public assessment report (EPAR) for Vfend. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vfend.
Therapeutic Indication
### Therapeutic indication Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: - treatment of invasive aspergillosis; - treatment of in candidaemianon-neutropenic patients; - treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei); - Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp. Vfend should be administered primarily to patients with progressive, possibly life-threatening infections. Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
Therapeutic Area (MeSH)
ATC Code
J02AC03
ATC Item
voriconazole
Pharmacotherapeutic Group
Antimycotics for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| voriconazole | N/A | 伏立康唑 |
EMA Name
Vfend
Medicine Name
Vfend
Aliases
N/A